Dendritic Cells and T Cells in Immunotherapy
Overview
Authors
Affiliations
Autologous cellular immunotherapies have been used experimentally in humans to treat many types of cancer. These therapies are divided into two principal types: active cellular immunotherapies that rely on autologous dendritic cells or other antigen presenting cells; and adoptive T-cell therapies, in which large numbers of antigen-specific T lymphocytes are propagated ex vivo and then infused back into the patient. With the FDA approval of the antigen presenting cell vaccine sipuleucel-T for prostate cancer, active immunization has become an accepted approach for the treatment of established cancer.
Chesson C, Zloza A Nanomedicine (Lond). 2017; 12(23):2693-2706.
PMID: 29098928 PMC: 5704090. DOI: 10.2217/nnm-2017-0254.
Henry J, Labarthe M, Meyer B, Dasgupta P, Dalgleish A, Galustian C Immunology. 2013; 139(3):377-85.
PMID: 23374145 PMC: 3701184. DOI: 10.1111/imm.12087.
Effects of 4-1BB signaling on the biological function of murine dendritic cells.
Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Chen H Oncol Lett. 2012; 3(2):477-481.
PMID: 22740935 PMC: 3362585. DOI: 10.3892/ol.2011.506.